Danaher (DHR)
(Delayed Data from NYSE)
$246.58 USD
+0.78 (0.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $246.46 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$246.58 USD
+0.78 (0.32%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $246.46 -0.12 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Zacks News
Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products.
Honeywell (HON) Q1 Earnings Beat, Aerospace Sales Rise Y/Y
by Zacks Equity Research
Honeywell's (HON) first-quarter 2024 revenues increase approximately 3%, driven by strong momentum in the Aerospace Technologies segment.
The Zacks Analyst Blog Highlights Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power
by Zacks Equity Research
Danaher, Regeneron Pharmaceuticals, Palo Alto Networks, Workday and American Electric Power are part of the Zacks top Analyst Blog.
Top Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
Danaher (DHR) Q1 Earnings Beat, Biotechnology Sales Dip Y/Y
by Zacks Equity Research
While Danaher (DHR) surpasses first-quarter earnings and revenue estimates, its performance is hurt by a decrease in core sales in the Biotechnology segment.
Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Danaher (DHR) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Danaher (DHR) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Danaher (DHR) delivered earnings and revenue surprises of 11.63% and 2.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Honeywell (HON) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
Honeywell's (HON) first-quarter results are likely to have benefited from strength across most of its businesses. Weakness in the warehouse automation market might have been a spoilsport.
Why Danaher (DHR) Might Surprise This Earnings Season
by Zacks Equity Research
Danaher (DHR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Danaher (DHR) Gears Up to Post Q1 Earnings: Is a Beat Likely?
by Zacks Equity Research
Danaher's (DHR) Q1 earnings are likely to be hurt by weakness in the Biotechnology unit. Improving supply chains and strong price realization are expected to be positives.
Carlisle (CSL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Carlisle (CSL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Curious about Danaher (DHR) Q1 Performance? Explore Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Danaher (DHR) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Reasons Why Danaher (DHR) Should be in Your Portfolio Now
by Zacks Equity Research
Danaher (DHR) is set to benefit from strength across its businesses, acquired assets and shareholder-friendly policies.
Here's Why Danaher (DHR) Gained But Lagged the Market Today
by Zacks Equity Research
In the closing of the recent trading day, Danaher (DHR) stood at $244.28, denoting a +0.98% change from the preceding trading day.
Investors Heavily Search Danaher Corporation (DHR): Here is What You Need to Know
by Zacks Equity Research
Danaher (DHR) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GE Aerospace (GE) Debuts as Aviation-Focused Public Company
by Zacks Equity Research
GE Aerospace (GE) commences its business operations as an independent public company, following the spin-off of the GE Vernova business from General Electric.
Danaher (DHR) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
In the closing of the recent trading day, Danaher (DHR) stood at $245.94, denoting a -0.75% change from the preceding trading day.
3M (MMM) Completes Divestiture of Its Healthcare Business
by Zacks Equity Research
3M's (MMM) divestment of the healthcare business will enable it to focus more on its core businesses.
Is Invesco Global Water ETF (PIO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PIO
Danaher (DHR) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Danaher (DHR) reachead $248.77 at the closing of the latest trading day, reflecting a +0.12% change compared to its last close.
Wall Street Analysts See Danaher (DHR) as a Buy: Should You Invest?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Danaher (DHR). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Danaher (DHR) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Danaher (DHR) reachead $248.46 at the closing of the latest trading day, reflecting a +0.27% change compared to its last close.
Here is What to Know Beyond Why Danaher Corporation (DHR) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Danaher (DHR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
The latest trading day saw Danaher (DHR) settling at $251.68, representing a -0.81% change from its previous close.
Why Danaher (DHR) Outpaced the Stock Market Today
by Zacks Equity Research
The latest trading day saw Danaher (DHR) settling at $251.47, representing a +0.83% change from its previous close.